Profile data is unavailable for this security.
About the company
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
- Revenue in INR (TTM)16.79bn
- Net income in INR107.27m
- Incorporated1995
- Employees1.69k
- LocationNectar Lifesciences LtdSco 38-39,, Sector 9-DCHANDIGARH 160009IndiaIND
- Phone+91 1 723047777
- Fax+91 1 723047755
- Websitehttps://www.neclife.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZIM Laboratories Ltd | 3.88bn | 161.50m | 5.02bn | 556.00 | 31.14 | 2.07 | 14.80 | 1.29 | 3.31 | 3.31 | 79.19 | 49.82 | 0.9788 | 2.67 | 5.18 | 6,980,632.00 | 4.07 | 3.88 | 5.70 | 6.54 | 53.95 | 47.45 | 4.16 | 3.97 | 0.9475 | 2.77 | 0.3004 | 1.21 | -7.80 | 1.84 | -29.42 | 2.37 | 29.41 | -- |
| Lyka Labs Ltd | 1.32bn | 33.80m | 5.05bn | 423.00 | 153.48 | 5.11 | 40.80 | 3.84 | 0.9226 | 0.9226 | 37.94 | 27.71 | 0.8222 | 6.01 | 3.92 | 3,111,116.00 | 1.95 | -5.48 | 2.50 | -8.30 | 59.65 | 60.82 | 2.38 | -9.16 | 1.23 | 2.34 | 0.2627 | -- | 19.47 | 9.45 | 81.16 | -- | 13.88 | -- |
| Accent Microcell Ltd | 2.62bn | 325.33m | 5.06bn | 174.00 | 12.14 | 2.84 | 14.10 | 1.93 | 19.80 | 19.80 | 141.04 | 84.68 | 1.65 | 4.64 | 6.67 | 15,070,950.00 | 20.43 | -- | 24.77 | -- | 32.30 | -- | 12.41 | -- | 4.81 | -- | 0.0114 | -- | 24.45 | -- | 146.63 | -- | -- | -- |
| Medicamen Biotech Ltd | 1.82bn | 64.80m | 5.49bn | 378.00 | 60.80 | 2.53 | 39.76 | 3.02 | 7.10 | 7.10 | 165.42 | 170.67 | 0.6199 | 1.67 | 2.76 | 4,804,595.00 | 1.99 | 5.89 | 2.76 | 8.45 | 46.53 | 36.54 | 3.22 | 9.58 | 1.41 | 2.67 | 0.0854 | 8.46 | 27.29 | 7.90 | -26.36 | -1.89 | -16.71 | 0.00 |
| IND Swift Laboratories Ltd | 7.26bn | 3.73bn | 6.07bn | 47.00 | 1.62 | 0.600 | 1.52 | 0.836 | 63.24 | 63.24 | 123.25 | 171.20 | 0.486 | 1.73 | 2.54 | 154,462,200.00 | 25.01 | 5.00 | 29.88 | 6.13 | 46.23 | 41.12 | 51.47 | 8.52 | 3.51 | 7.87 | 0.016 | 0.00 | 6.10 | 11.10 | 784.44 | 70.82 | 23.60 | -- |
| Sakar Healthcare Ltd | 1.64bn | 124.03m | 6.20bn | 325.00 | 50.15 | 2.01 | 19.43 | 3.77 | 5.68 | 5.68 | 75.48 | 141.51 | 0.4312 | 3.22 | 7.45 | 5,052,619.00 | 3.25 | 5.26 | 3.85 | 6.28 | 44.83 | 43.47 | 7.55 | 10.12 | 0.6515 | 3.28 | 0.2374 | -- | 14.99 | 17.58 | -8.53 | 11.76 | 19.05 | -- |
| Wanbury Ltd | 5.77bn | 529.62m | 6.99bn | 1.49k | 13.57 | 18.05 | 10.57 | 1.21 | 15.73 | 15.73 | 173.33 | 11.83 | 1.55 | 7.95 | 6.17 | 3,871,231.00 | 14.26 | 11.63 | 39.18 | -- | 49.84 | 42.46 | 9.18 | 7.62 | 0.6908 | 1.71 | 0.8235 | -- | 15.21 | 8.02 | 638.26 | -- | 29.87 | -- |
| Albert David Ltd | 3.65bn | 685.47m | 7.28bn | 1.50k | 10.61 | 1.76 | 9.63 | 1.99 | 120.12 | 120.12 | 639.84 | 724.06 | 0.7377 | 2.83 | 10.89 | 2,439,081.00 | 13.85 | 10.00 | 17.15 | 13.15 | 66.12 | 59.85 | 18.77 | 11.87 | 3.65 | 53.46 | 0.0085 | 12.89 | 6.12 | 2.72 | 108.49 | 33.59 | 40.87 | 13.90 |
| Nectar Lifesciences Ltd | 16.79bn | 107.27m | 7.69bn | 1.69k | 71.93 | 0.7133 | 10.71 | 0.4578 | 0.4766 | 0.4766 | 73.70 | 48.06 | 0.7764 | 1.67 | 4.94 | 9,960,952.00 | 0.496 | -0.2956 | 0.8778 | -0.541 | 30.41 | 16.49 | 0.6388 | -0.4053 | 0.5576 | 1.25 | 0.3686 | -- | 10.53 | -9.56 | 120.66 | -36.29 | -5.06 | -- |
| Kopran Ltd | 6.36bn | 528.93m | 9.63bn | 358.00 | 15.05 | 1.93 | 14.26 | 1.51 | 13.26 | 13.26 | 150.57 | 103.15 | 0.8922 | 2.76 | 3.64 | 17,765,300.00 | 7.42 | 8.47 | 10.49 | 12.23 | 35.38 | 32.93 | 8.32 | 8.89 | 1.27 | 29.83 | 0.1997 | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Kotak Mahindra (UK) Ltd.as of 30 Sep 2024 | 2.39m | 1.06% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 43.90k | 0.02% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 30.47k | 0.01% |
| American Century Investment Management, Inc.as of 07 Nov 2024 | 2.21k | 0.00% |
